Lately, TNFoL has been the focus of studies of autoimmunity; its role in the progression of autoimmune diabetes is, however, still unclear. To analyze the effects of TNFoL in insulin-dependent diabetes mellitus (IDDM), we have generated nonobese diabetic (NOD) transgenic mice expressing TNFe¢ under the control of the rat insulin II promotor (RIP). In transgenic mice, TNFot expression on the islets resulted in massive insulitis, composed ofCD4+ T cells, CD8+ T cells, and B cells. Despite infiltration of considerable number of lymphoid cells in islets, expression of TNFc¢ protected NOD mice from IDDM. To determine the mechanism of TNFot action, splenic cells from control NOD and 1LIP-TNFc~ mice were adoptively transferred to NOD-SCID recipients. In contrast to the induction of diabetes by splenic cells from control NOD mice, splenic cells from 1LIP-TNF(x transgenic mice did not induce diabetes m NOD-SCID recipients. Diabetes was induced however, in the 1LIP-TNFo~ transgenic mice when CD8+ diabetogenic cloned T cells or splenic cells from diabetic NOD mice were adoptively transferred to these mice. Furthermore, expression of TNFcx in islets also downregulated splenic cell responses to autoantigens. These data establish a mechanism of TNFcx action and provide evidence that local expression of TN&x protects NOD mice from autoimmune diabetes by preventing the development ofautoreactive islet-specific T cells.
I
nsulin-dependent diabetes mellitus (IDDM) 1 is an autoimmune disease in which self-reactive lymphocytes mediate the complete destructaon of pancreatic [3 cells (reviewed in reference 1). A considerable body of evidence suggests that IDDM is determined by both genetic and environmental factors. Of the genes involved, the strongest association between IDDM is found between genes of the major histocompatibility complex (MHC), and specifically HLA-DQ in humans (2) . However, a multitude of studies show that IDDM is a polygenic disease and in addition, studies with identical twins show a concordance on the order of 30-50%, suggesting that environmental factors play a key role in the development of diabetes (3) .
The study of IDDM has been greatly facilitated by the availability of good animal models (4) (5) (6) (7) . The Biobreeding (BB) rat and the nonobese diabetic (NOD) mouse develop a form of IDDM that is broadly similar to the human disease. The NOD mouse has been the focus of considerable 1Abbrevzat~ons used in ttus paper" BB, blobreeding; DLN, draining lymph nodes; GAD, glutamxc acid decarboxylase; IDDM, msuhn-dependent diabetes mellitus; NOD, nonobese diabetic; PLN, perapheral lymph nodes; RIP, rat insulin II promotor. attention since it shows a reproducibly high frequency of &sease (80-90% of females and 50-60% in males) (4) . In the NOD mouse, the islets of Langerhans become infiltrated with lymphoid cells, first around the islet (peri-insulitis) around 3-4 wk, which gradually intensifies to insulitis. [3 cell destruction follows and results in the loss of detectable insulin and, the onset of overt diabetes, which plateaus at "-'4-6 mo of age. Genetic analysis shows that NOD diabetes is also a polygemc disease (8, 9) . Of the genes involved in diabetes, the MHC (Idd-1), plays a key role (10) (11) (12) . Like diabetes-susceptible humans, the NOD mouse expresses an unusual MHC class II I-A allele (the mouse homologue of HLA-DQ), which carries a small amino acid residue (S) at position 57; this parallel structure between these two susceptibility alleles has further supported the relevance of the NOD model to human disease (7, 13) . The use of modern genetic methods has led to the identification of other recessive loci which predispose to IDDM. Thus, genes have been identified on chromosomes 3, 7, 11, and 14 which appear to play a cumulative role in increasing the frequency of IDDM. Several of these genes, notably ldd-3 and Idd-10 on chromosome 3, predispose to insulitis and diabetes, whereas Idd-5 seems to predispose predominantly to insulitis (8, 14) . Insulitis and diabetes are not 100% correlated, there are certain strains of NOD mice such as NOD/WEHI which seem to show insulitis but little diabetes (15) . These results are broadly consistent with the concept that insulitis may be necessary, but possibly not sufficient for the induction of diabetes. However, the interpretation of these kinds of results is complex, given that the frequency of diabetes in NOD mice is notoriously variable from location to location, and strongly influenced by numerous factors even including diet (4) .
A considerable amount of data associates cytokines with the pathogenesis of IDDM, some of which is focussed on the cytotoxic effects ofcytokines on islet [3 cells (16-20) . In contrast to the cytotoxic effects of cytokines, a protective role of cytokines in diabetes in genetically diabetic prone NOD mice and BB rats has also been postulated (20) . TNFc~ has been implicated in many pathological and physiological processes and has been the focus of many studies for past few years; its role in exacerbation or protection of IDDM is however not clear. TNFo¢ is a potent inflammatory mediator which activates endothelial cells in vitro to express a number of leukocyte adhesion molecules, including E-selectin, VCAM-1, and ICAM-1 (21) . It also strongly upregulates the level of MHC class I on a variety of different cell types, including islets (22) . Although TNFR does not increase the level of MHC class II, it can synergize with IFN-y to cause upregulation of MHC class II on islets (23) . The proinflammatory properties of TNFo~ in vitro are reflected in vivo. Thus, transgenic mice expressing TNF in a multitude of tissues, including synovia and the islets of Langerhans, exhibit a pronounced infiltration of inflammatory cells (24) (25) (26) (27) . In fact, detailed studies of transgenic mice in which the rat insulin promoter (RIP) directed the synthesis of TNFoL or TNF[3 showed that these molecules direct the recruitment of CD4 and CD8 T cells as well as B cells and cause upregulation of MHC class I but not MHC class II (25) (26) (27) . These transgenic mice appear to express the transgene locally since circulating levels ofcytokines are not detectable, and cultured islets from transgene positive, but not from transgene negative mice, express significant levels of TNFot. Nonetheless, the infiltrate induced by TNFot does not lead to diabetes in these transgenic mice.
Despite the proinflammatory properties of TNFoL in vitro and in vivo in transgenic animals, Jacob et al. showed, surprisingly, that TNFoL retarded the development of IDDM in adult NOD mice, when administered in pharmacologic doses (28) . This striking result suggested that the inflammatory properties of TNF~x in fact have an inhibitory rather than a stimulatory effect on diabetes development. However, the fact that this cytokine was presented systemically confounds the interpretation of these studies. Specifically, it could be argued that the cytokines effects are distant rather than local at the islets of Langerhans, and could for example result in the recruitment of leukocytes away from that tissue, because of the activation of endothelia elsewhere. Systemic administration of cytokines can also act indirectly on the immune system, for example IL-1 and TNFe~ can increase the secretion of adrenocorticotropic hormone by
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Prevention of Diabetes by stimulating the hypothalamic-pituitary axis which suppresses inflammatory cells and cytokines (29) . Alternatively, the effects of systemic TNFo~ could nonetheless be mediated through direct events in the islets of Langerhans. In addition, a recent demonstration of exacerbation of development of diabetes, when TNFoL administered early starting with neonatal NOD mice, indicates the complex effects of TNFoL on IDDM (30) . Results showing a controversial role of TNFcx by pharmacological administration of TNFcx were further complicated by finding that when pharmacologic doses of monoclonal anti-TNFot antibodies were administered for 4 wk, the incidence of diabetes in NOD mice was significantly reduced. On the other hand, when anti-TNFc~ antibodies were administered for a period of 8 wk, the incidence of diabetes was significantly increased (31) , and diabetes were completely prevented when antiTNFot monoclonal antibodies were administered neonatally (30) . To address the effect of local TNFoL in islets of NOD mice and determine the mechanism of action of TNFoL in IDDM, we generated transgenic mice in which the TNFot gene was directed by the RIP and injected directly into NOD mice. To our surprise, the resulting NOD mice show pronounced resistance to spontaneous IDDM. However, they remain susceptible to adoptive transfer of IDDM with mature effector cells. These results therefore support the notion that locally produced TNFot protects islets from diabetes by inhibiting the development of auto-aggressive T cells.
Materials and Methods
Mice. NOD mice ongmally obtained from Jackson Laboratones (Bar Harbor, ME) were bred in our colony. All mice used in this project were housed in specific pathogen-free conditions. In our colony, female NOD mice develop diabetes from 12 wk of age reaching 90% by 24 wk. NOD-SCID mice were obtained from the Jackson Laboratories. RIP-TNFc¢ transgenic mice were generated by us, and both transgenic positive and non-transgemc litter mates were housed in specific pathogen-free condmons m our NOD colony.
Generation of Transgenic Mice. RIP-TNF<x transgenic mice were generated as described previously (27) . In brief, the locus encoding murine TNFe~ were derived from EMBL 7 clone 13 subcloned into pUC-12. The TNFoL gene was isolated as a 2.7-kb NarI/SaI fragment and subcloned into ClaI/SalI sites in pSK-RIP. This construct was used previously to generate IKIP-TNFoL transgenlc mice in (C57BL/B X CBA)F2 mice (27) ; in these mice TNFo~ was faithfully expressed under the control of RIP as reported earlier (27) . For this project transgenic mice were directly constructed in NOD background by injecting femhzed NOD eggs with the same construct. Several transgene posinve founder lines were established by screening mice for expression of R.IP-TNFcx by Southern analysis of DNA extracted from tails. One of the founder hnes (V 93.3) was crossed with NOD and offsprings were monitored for IKIP-TNF<x expression. Both transgene posmve and negative progeny were housed under the same conditions and were monitored for the phenotyplc effects.
Measurement of TNFoe Secretion by Islets. Islets were isolated by collagenase digestion of whole pancreata. 100-150 islets were cultured in 0.5 ml of DMEM containing 20 mM glucose and 10% fetal calf serum for 24 h, as previously described (27) . Supernatants were collected and analyzed for presence of TNFIx by ELISA methods. ELISA procedures were performed by using antibodies obtained from PharMingen (San Diego, CA) and their recommended protocols were followed.
Immunohistochemistry and Assessment of lnsulitis. Insulitis was assessed by histology. Pancreata were prepared for histological analysis by either immediate freezing of the tissue in OCT compound over dry ice or by fixing in 10% formalin and then embedding in paraffin as described previously (26) . Paraffin embedded blocks were sectioned and stained with hematoxylin and eosin. The shdes were viewed by light microscopy for presence and pattern of msulitis. Frozen sections were prepared for evaluating presence of CD4 and CD8 T cells, B cells and macrophages in islet infiltrates. Monoclonal antibodies (conjugated with biotin) against CD4, CDS, macrophage(F/480) and B220 markers were used to stain frozen sections and slides were developed and processed as described previously (26) .
Diabetes Measurements. Diabetes was assessed by weekly measurement of unne glucose by using Dlastix (Ames, Elkhart, IN), and diabetes was confirmed by blood glucose measurements. Mice were considered to be diabetic if three consecutive measurements of blood glucose were greater than 250 g/dl. To eliminate possible artifacts caused by environmental components such as food, transgene positive and transgene negative mice were housed together; we reasoned that any artefact of this nature would be localized to individual cages, and therefore would randomize across transgene positive and transgene negative mice.
Flow CytometricAnalysis. Single cell suspensions of spleen, peripheral lymph nodes, blood, and thymus tissue were prepared from 6-8-wk-old NOD or RIP-TNFci transgenic mice. Cells were stained by incubating for 45 mm at 4°C with ant-CD4-PE, antl-CD8-FITC, and B220-Biotin. Cells were subsequently washed and fixed in 1% formaldehyde. Samples were analyzed on a Becton Dickinson FACS ® star plus Flowcytometer. A minimum of 10,000 cells were collected for each sample.
Leukocyte Isolation and Counts. Single cell suspensions from spleen, thymus, penpheral lymph nodes (cervical, axillary, inguinal, and periaortic), and mesentenc lymph nodes were prepared and the number of cells were determined using a hemocytometer. Blood samples were obtained by puncture of the retro orbital plexus of anesthetized mice.
T Cell Proliferation Assay. For polyclonal stimulation of T cells, 5 × 105 splenic cells were cultured in presence of 2.5 Ixg/ml ConA or 3 p~g/ml antl-CD3 in 96-well plates in Bruffs medium supplemented with 5% FCS, 2 mM glutamine, 100 U/ml penicflhn, 100 p,g/ml streptomycin, and different concentrations of the antigen. Proliferation was measured by addition of 1 p~Ci of [3H]thymidine (International Chemical and Nuclear, Irvine, CA) for the last 18 h ofa 5-d culture, and incorporation of radioactivity was assayed by liqmd scintillation counting. For anti-KLH responses, mice were lmmumzed with 100 p~g KLH in a 1:1 emulsion with CFA, containing 1 mg/ml Mycobacterium tuberculosis strain H37Ra, (Difco Laboratories, Detroit, MI) in the hind footpads. After 9 d, the popliteal lymph nodes were removed and cell suspensions were prepared. The lymph node cells were cultured (5 × 10 s per well) in various concentration of KLH in bruffs mechum supplemented with 5% FCS. Proliferanon was measured by uptake of [3H]thymidine as stated above.
T Cell Proliferation in Response to Islet Extracts and GADp524-543. Spleen cell proliferation in response to islet extracts or
GADp524-543 (SRLSKVAPVIKARMMEYGTT) were measured by cultunng spleen cells (1 × 106/well) obtained from R.IPTNFot transgenic or non-transgenic mice in HL-1 serum-free medium as described (32) . Islet cell extracts were prepared by isolating islets by collagenase digestion of whole pancreata, as previously described (27) followed by sonication of single cell preparation of islets and five cycles of freeze thaw. Proliferation of spleen cells was measured in 5-d culture by uptake of [3H]thymidine as mentioned above.
Cytokine Assays. Assays for cytokine production by spleen cells from RIP-TNFo~ transgenic or non-transgenic mice were done by culturing 1 × 10 s purified CD4+ T cells with 5 X 105 irradiated (3,000 R) splenic cells from unlmmumzed NOD mice and different amounts of the GADp524-543 in Bruffs medium, supplemented as described above. After 24 h of culture, 100 ~1 of culture supernatant was removed from each well for IL-2 measurements. For IL-4 and IFN~/measurements, supernatants were removed after 4 d of culture. ELISA method was used to determine cyto~ne levels in supernatants, using antibodies from PharMingen, and using their recommended protocols.
Anti-GADp524-543 Antibodies Analysis by ELISA. Anti-GADp524-543 levels were determined by specific ELISA method. Briefly, 96-well plates were coated with 10 ~xg/ml GADp524-543 for 24 h. Plates were then washed and blocked with 1% FCS in PBS. Diluted serum samples were then added to triplicate wells and plates were incubated for 1 h at 37°C. Plates were washed and the antigen specific antibody titers determined with the biotin conjugated goat anti-mouse-Ig detection antibody (Southern Biotechnology, Birmingham, AL). ELISA was developed by using streptavidm conjugated horse radish peroxidase and Elisa T-Turbo developing reagent substrate (ICN Biomedlcals, Inc., Costa Mesa, CA). Plates were analyzed on a Dynatech MR700 ELISA plate reader (Dynatech Labs., Inc., Chantilly, VA).
Generation and Propagation of CD8 Diabetogenic T Cell Clones.
The CD8 diabetogemc T cell clones used in this project are well characterized (33) and cause rapid diabetes upon adoptive transfer to NOD-SCID mice. These clones were generated from islet mfiltrates of 7-wk-old females as described by us previously, and were routinely maintained by our laboratory (33) .
Adoptive Transfer of Diabetes. Adult female RIP-TNFo~ transgenic and non-transgenic litter mates and NOD-SCID mice were used as recipients. In some experiments, recipient mice were irradiated with 725 rad from a caesium source. Spleen cells from diabetic NOD or non-diabetic NOD or from RIP-TNFot mice (6-10 × 106 cells/mouse ) or CD8 cloned T cells 6 × 106 were adoptively transferred intravenously to recipient mice. Non-irradiated recipients were examined for diabetes on a weekly basis and irradiated recipient mice were monitored for diabetes daily after adoptive transfer.
Results

Generation of Transgenic NOD Mice Expressing RIP-TNFa.
We used the same construct that we have described previously that directs the expression of substantial levels of TNFct in (C57BL/6 × CBA)F2 mice (27) . In our previous study we constructed several lines of transgenic mice in which the expression of this gene showed reproducible production of TNFot from the pancreas but not from other tissues tested. Specifically, this transgene was expressed at the level of RNA and protein in pancreatic tissue, and as biologically active TNFo~ in supernatants from cultured islets. In situ hybridization in those studies showed that the Figure  1 . Production of TNF(x by islets from 1LIP-TNFc¢ transgemc mace. Islets from RIP-TNF(x transgemc mace (R) or from negative litter mate control NOD mace (~1) ranging m age from 4 wk to 13 wk were examreed for TNF(x secretion. Islets pooled from four mice were cultured for 48 h in 0.5 ml of culture medium contamlng 20 mM glucose. Amount of TNF(x secreted in supematants at a dilution of 1:10 were determined by TNFc~-speclfic ELISA.
TNFo~ expression in the islets was localized to the islets and not to the infiltrating mononuclear cells which developed in these animals. Fertilized NOD eggs were injected with this validated construct, and several transgene positive founder lines were obtained. Transgene founders were crossed with NOD mice and their progeny was examined for expression of RIP-TNFe¢ by Southern analysis (27) . After preliminary characterization, line V 93.3 was selected and further bred with NOD mice to monitor the phenotypic effects. Expression of TNF(x protein by islets was determined by analyzing supernatants from cultures containing islets from transgene positive or negative litter mates in the presence of glucose. A considerable amount of TNFot was secreted by islets obtained from RIP-TNFot transgenic mice after 48 h of culture, whereas no TNFot was produced by the islets of control mice cultured under similar conditions (Fig. 1) . These results indicate that TNFct is expressed and secreted by islets oftransgene positive mice. To determine at what age TNFo~ is first expressed in RIP-TNF(x mice, islets obtained from mice of various ages were tested for production of TNFot in vitro. TNFa could not be detected in mice of 4 wk old, whereas measurable amounts of TNFot was detected at 7 wk of age and at later time points (Fig. 1) . In addition, serum from these mice was also tested to determine levels of TNF(x. No TNFo~ could be detected in serum of transgenic mice at any age (data not shown). This result indicates that TNF(x is only locally expressed in islets of Langherhans.
Expression of TNFe¢ in the Pancreas of Transgenic NOD Mice Results in Insulitis.
Our previous studies indicated that the RIP-TNFoL transgene mediates dramatic infiltration of lymphocytes in the islets of Langerhans in mice generated on the (C57BL/6 × CBA)F2 background that had been back crossed to C57BL/6 (27) . We therefore monitored the effects of RIP-TNFot transgene on insulitis as a function of age in NOD mice. Histological examination of pancreata from 1LIP-TNFoL transgenic mice reveals that mononuclear PrevenUon of Diabetes by Transgene Encoded cells begin to infiltrate into islets at ~7 wk old. This infiltration (insulitis) was restricted to islets and it was not observed in surrounding acinar tissues (Fig. 2) . In contrast to non-transgenic NOD mice, the immune cell infiltrate in 1LIP-TNFc~ transgenic mice progresses to massive infiltration, almost completely obscuring the islets. The nature of the infiltrating cells was determined by immunohistochemical staining of frozen pancreata. Immunohistochemical staining shows the presence of numerous CD4 and CD8 cells as well as B220+ cells in the infiltrates of RIP-TNFoL transgenic mice (data not shown).
Infiltration of Mononuclear Cells into Islets in RIP-TNFa Transgenic Mice Does Not Prevent Insulin Production.
To ascertain whether the massive infiltration of mononuclear cells in islets of RIP-TNFc~ transgenic mice affects functioning of the beta cells in RIP-TNFa transgenic mice, we analyzed paraffin embedded sections of pancreata from 1<IP-TNFc~ mice for insulin and glucagon by immunocytochemistry (Fig. 3) . Examination of the sections from control NOD mice showed the presence of glucagon-producing cx cells aligned along the perimeter of the islet capsule, and considerable damage to insulin-producing 13 cells were predominantly in the central portion of the islet, indicating normal organization of e¢ and 13 cells in these sections. By contrast, sections from RIP-TNFot transgenic mice revealed no damage to 13 cells or loss of insulin content in is-lets; however the organization of the glucagon producing cells was disrupted (with ot cells located within islets) as we described previously for the tLIP-TNFot transgenic mice on the B6 background (27) . Thus, in spite of massive mononuclear infiltration of islets in P, IP-TNFc~ mice, their 13 cell physiology remains normal.
Expression of TNFo~ in Islets Prevents the Development of Spontaneous Diabetes in NOD Mice. RIP-TNFoL transgene
positive and non-transgenic litter mates were then housed under the specific pathogen-free conditions used for our NOD colony and monitored for the development of diabetes. Since female mice develop diabetes at a significantly greater frequency than male NOD mice, we monitored only females in this study. Expression of TNF-ot in islets dramatically retarded the development of IDDM. Whereas ~80% of female NOD transgene-negative mice developed diabetes by 25 wk, at this time only ~'-,15% of transgene positive animals developed disease. This study was performed with two separate groups of animals, both of which are summarized in Fig. 4 . Thus, whereas transgenic TNFot mediated substantial infiltration into the islets of Langerhans, this did not lead to autoimmune diabetes. that the protection offered by the RIP encoded transgene (TNFo 0 may be due to general suppression of the immune system. To rule out this possibility, we used an antigenspecific system to measure T cell responses of RIP-TNFei transgenic mice to a well-characterized foreign protein antigen, keyhole limpet hemocyanin (KLH). Mice were immunized with KLH in complete Freund's adjuvant (CFA) and 9 d later their draining lymph nodes (DLN) were tested for in vitro recall proliferative responses. RIP-TNFci transgenic mice exhibited recall prohferative responses similar to that ofnon-transgenic litter mates, indicating that local expression of TNFot in islets does not lead to the induction of suppression of immune responses to foreign protein antigens (Fig. 6) . Thus, these data suggest that expression of TNFot in islets does not cause general suppression of the immune system.
Expression of TNFa in the Pancreas of Transgenic NOD Mice Has No Effects on the Number of Lymphocytes in Lymphoid Or
Expression of TNFce in Islets Inhibits the Development of Immune Responses to Islets and GAD Peptide.
Although the studies presented above show that responses to foreign protein antigens in RIP-TNFcl transgenic mice are not significantly different from negative litter mate controls, the possibihty that specific regulatory mechanisms could suppress islet specific autoimmune responses remained an explanation for suppression of IDDM by IklP-TNFot transgene. To address this we examined the spontaneous T cell responses and serum antibody levels to a synthetic peptide derived from glutamic acid decarboxylase (GAD), containing amino acid sequence 524-543 (GADp524-543). Spontaneous immune responses to this peptide in young NOD mice has been shown previously (32) . To determine whether spontaneous responses to GADp524-543 are mhibited by local expression of TNFoL in islets, splenic cells from both 1LIP-TNFot and non-transgenic litter mates were examined for proliferation and cytokine production in response to in vitro challenge with this peptide. Splenic cells from RIP-TNFcx mice showed a complete lack of proliferative responses to GADp524-543, whereas a signifiopment, we carefully examined the various subpopulations oflymphocytes in lymphoid organs in P, IP-TNFot transgenic mice. Both R.IP-TNF~x transgenic and non-transgenic mice were examined for the number and ratios of CD4, CD8, and B220 positive cells in spleen, peripheral lymph nodes (PLN), thymus and blood by Flow cytometry. The frequency of various subsets of lymphocytes in RIP-TNFo~ and non-transgenic litter mates were indistinguishable, indicating that local expression of TNFc~ in islets does not influence the development of lymphoid tissues in NOD mice (Fig. 5) . In addition, in vitro proliferative responses of PLN cells to CD3 and ConA were measured, and the data presented in Table 1 indicates that in vitro T cell proliferation in response to polyclonal stimulators is normal in RIPTNFoL transgenic mice.
Expression of TNFa in the Pancreas of Transgenic NOD Mice Does Not Induce Generalized Immunosuppression.
Since expressrun of TNFot in islets prevents the development of spontaneous diabetes in transgenic mice, one could argue cant response was apparent in the spleen of non-transgenic litter mates (Fig. 7 A) . Splenic ceils from non-transgenic NOD mice, showed significant production of IL-2, IL-4, and IFNy, whereas no such production of cytokines could be detected from spleen cells from R.IP-TNFot transgenic mice (Fig. 7, B-D) . In addition, serum from both nontransgenic and 1KIP-TNFoc transgenic mice were tested for the presence of anti-GAD antibodies. The levels of antiGADp524-543 antibodies were significandy lower in RIPTNFot transgenic mice when compared with non-transgenic litter mates (Fig. 7 e) . In addition, proliferative responses of splenic cells from 1KIP-TNFot and non transgenic litter mates were measured against islet extracts obtained from NOD mice or from 1KIP-TNFc~ transgenic mice. Again a lack of proliferative response was seen in 1KIP-TNFot transgenic mice, whereas non transgenic mice responded well (Fig. 7 a) . These results demonstrated that local expression of TNF~x had profound effect on the development of autoantigen specific immune responses in both the B and T cell compartments. Moreover, since splenic cells from KLH ~tglrnl non transgenic mice were able to proliferate in response to islets from RIP-TNFct transgenic mice, it can be concluded that expression of TNFot does not change the antigenic moieties present on or in the islets. 
Transfer of Diabetes by Adoptive Transfer of Sple,,ic Cells Adoptively Transferred Splenic Cells from RIP-TNFa Transgenic Mice Fail to Cause Diabetes in NOD-SCID Mice.
To understand the mechanism of protection offered by local expression of TNF(x in islets, we adoptively transferred splenic cells from diabetic NOD mice or from age matched RIPTNFo~ transgenic mice to NOD-SCID recipients. When diabenc splenic cells from NOD mice were transferred into NOD-SCID recipients, diabetes developed within 2-3 wk, whereas age matched splenic cells from P,.IP-TNFot mice failed to cause diabetes in NOD-SCID recipients (Table 2) . We also adoptively transferred splenic cells from age matched non-diabetic, non-transgenic mice to NOD-SCID mice, and again diabetes developed in recipient mice, although, the development of diabetes was slower than that induced by splenic cells from diabetic NOD mxce. These results suggest that sensitized autoreactive T cells having the potential to cause diabetes were present in the spleens of NOD mice while the splenic cell population from P,.IP-TNFot transgenic mice lacked this capabihty. The inability of spleen cells from R.IP-TNFot transgenic mice to cause diabetes in NOD-SCID recipients on adoptive transfer could be explained at least by two possible mechanisms: either autoreactive cells with the potential to cause diabetes fail to develop in RIP-TNFo~ transgenic mice, or autoreactive cells are present in the spleens of P,.IP-TNF(x transgenic mice but these cells are prevented from attack in the islets of the recipient mice by some kind of regulatory mechanism. In addition, these results also suggested that TNFo~ expression in islets is not required to protect islets from a destructive immune response.
To distinguish these possibilities, we adoptively transferred a mixture of diabetic spleen cells and spleen cells obtained from P, IP-TNFot mice to NOD-SCID recipients, and examined the development of diabetes in recipient mice. Admixture of spleen cells from diabetic mice with spleen cells from R.IP-TNFo~ mice did not prevent the development of diabetes (Table 2) , but delayed the development of diabetes by a few weeks. Although these results indicate that protection offered by local expression of TNF(x is not due to generation of potent specific regulatory suppressor cells, we cannot rule out the possibility of such regulation by these simple adoptive transfer experiments. To 6--10 X 10 6 splenic cells depleted of Pd3C form NOD (diabetic within two weeks) mice were transferred intravenously either alone or in the presence of the same amount ofsplemc cells from P.IP-TNF(x transgenic trace. Diabetes were monitored by urine glucose analysis at weekly intervals. 6 × 106 dxabetogemc cloned CD8+ T cells (G9-C8) or 10 × 106 splemc cells depleted RBC form NOD (diabenc wxthin two weeks) rmce were transferred intravenously to lrra&ated (725 Rads) ILIP-TNFc~ transgenic mice or negative htter mates. Diabetes was monitored by urine glucose analysxs at daffy intervals.
rule out the existence of specific regulatory cell mediated mechanism of protection by TNFci, further studies including a detailed kinetics analysis by using various ratios of cells will be needed.
Local Expression of TNFa Does Not Protect Islets against Effector Cells.
To determine if protection offered by local expression of TNFo~ in islets was mediated by the direct effects of TNFo¢ on the functioning of effector cells, we used an adoptive transfer system in which spleen cells from diabetic NOD mice, or cloned diabetogenic CD8 T cells (33) were used to transfer diabetes. Irradiated NOD or PdP-TNF0~ transgenic NOD mice were adoptively transferred with either cloned CD8 T cells or with diabetic splenic cells, and the development of diabetes was monitored (Table 3 ). In addition, non-irradiated recipients were also adoptively transferred with cloned CD8 T cells. Rapid development of diabetes occurred in all cases, indicating that TNFci does not block the functions of effector cells which are already primed in vivo (Table 4) .
Discussion
Since TNFo~ is a powerful mediator of inflammation with a pleiotropic range of actions, it is not surprising that this molecule has been found to be involved in autoimmunity. It is therefore of considerable interest that a few years ago Jacob et al. (28) and Satoh et al. (34) demonstrated that TNFIx, when administered in pharmacologic doses to adult NOD mice and BB rats (35) completely prevented the development of IDDM. However, the molecular and cellular basis for protection offered by TNF~x has not been explained. Recently, Yang et al. have shown that this situation is more complex, since administration of TNFc~ neonatally exacerbates the development of diabetes (30) . These studies implied that when TNFo~ is administrated early it potentiates the initiating events in the development oflDDM, but if administered late, it inhibits an effector phase of the disease which normally leads to destruction of islets. However, from the above studies it was not clear whether the effects of the systemic administration of TNFo~ were fundamentally pharmacologic in activity and regulated the autoimmune response at sites distal from islets or whether TNFot is mediating a local effect and playing a direct role in pathology of IDDM. We therefore generated transgenic mice directly in NOD mice by injection of the RIP-TNFci construct that we have successfully used previously in a non-autoimmune predisposed strain. After initial characterization, we have studied these mice for the development of autoimmune diabetes. We show here that the RIP-TNFot transgene prevents the development of diabetes in NOD mice and that TNFot itself is not required to be present to prevent the destruction of islets by autoreactive T cells. Rather, protection is mediated by intervention at earlier steps in the development of anti-islet specific autoimmu- 6 × 10 6 diabetogenic cloned CD8+ T cells (G9-C8) were transferred intravenously to RIP-TNFo~ transgenic mace. Diabetes were momtoried by urine glucose analysis at weekly intervals.
nity and not at the final effector phase. Our data are consistent with those of McDevitt and colleagues (28, 30) , who have shown that administration of TNFcx to adult NOD mice leads to protection of diabetes. Our RIP-TNFoL transgenic mice fail to express TNFo~ in the neonatal periods where TNFci exacerbates disease and only start to express TNFcx as adults (7 wk) at which time we also start to see infiltration in islets. There are a number of possible explanations for the absence of diabetes in the 1LIP-TNFo~ transgenic NOD mice. First, local expression of TNFci may inhibit the homing of autoreactive cells to the pancreatic islets; second, TNF0~ may not prevent the migration of autoreactive cells to islets but rather inhibit their ability to initiate or sustain islet specific destructive response; third, auto-reactive cells may fail to develop in the RIP-TNFo~ transgenic mice; fourth, TNFo~ may alter the properties of islets and make them resistant for destructive attack by autoreactive cells; fifth, TNFcx may down regulate expression of autoantigens on islets required for the recognition for successful destructive response; finally, expression of TNFci under the control of the RIP might lead to general suppression of the immune system or may directly alter the regulatory mechanism of the immune system.
Our data presented here provide evidence to rule out several of the possibilities mentioned above; they also further provide evidence for the mechanism whereby TNFci inhibits development of diabetes. The lack of development of diabetes in 1LIP-TNFci transgenic mice is not due to inhibition of the migration of leukocytes to the islets, since massive islet infiltration is seen in these mice, which is even more dramatic than in the control non-transgenic NOD mice. Moreover, infiltrating cells include CD4, CD8, and B220 positive cells, and the cellularity of this infiltrate is not different from the typical insulitis in control NOD mice (27) . Despite massive infiltration, immunohistochemistry indicates normal insulin levels and a lack of destruction of [3 cells in 1LIP-TNFo~ transgenic mice. These observations suggested that infiltrating cells in islets of RIP-TNF(~ mice were unable to initiate or sustain an autoimmune destructive response.
Local expression of TNFo~ in islets does not lead to the general suppression of immune responses, since in vitro proliferative responses of T cells from R.IP-TNFot are comparable to those of NOD mice. In contrast, whereas responses to KLH are normal in RIP-TNFo~ transgenic mice, specific autoimmune responses to the [3 cell autoantigen GAD and autoantigens contained in islet extracts were inhibited. RIP-TNFot transgenic mice showed reduced immune responses to islet auto-antigens since the antibody response, spleen cell proliferation and cytokine production to a peptide fragment of GAD is substantially reduced in these anireals along with lack of response to islet extracts. GADp524-543, GAD65, and islet extracts have been used previously to measure autoantigen specific responses of non-diabetes prone mice such as Balb/c, B10.GD, FI(NOD × Balb/c), and other inbred strains, and little to no response to these antigens was discovered when compared to the NOD strain (32, 36) . Also, GAD reactivity has been only shown to correlate with insulitis in NOD mice. Thus, our result suggests that TNFo~ abrogates, at least in part, the anti-islet immune response.
To determine if local expression of TNFot conferred a long-term protective effect by altering the development of autoaggressive cells, we adoptively transferred lymphocytes from age matched diabetic NOD, non-diabetic NOD or 1LIP-TNFci transgenic NOD mice to recipient NOD-SCID mice. Spleen cells from diabetic NOD mice induced diabetes in NOD-SCID mice rapidly, ~3 wk after transfer. However, spleen cells from age matched 1LIP-TNFci transgenic mice did not induce diabetes in these animals. These results indicate that sensitized autoreactive lymphocytes with the potential to cause diabetes were absent in RIPTNFc~ transgenic mice, suggesting that local expression of TNFoL prevents the development ofautoreactive cells.
These studies provide a potential explanation of the fascinating results of McDevitt's group (28) . Our data suggest first that the TNFc~ mechanism is mediated by local events in the islets of Langerhans since PdP-TNFo~ transgenic mice do not have detectable levels of systemic TNFci. We further show that the effect of TNFcx on the inhibition of development of disease is a long-lasting effect on the lymphocytes, rather than a short-term inhibition of effector function, since transfer of spleen cells from TNFci transgenic mice to NOD-SCID recipients does not provoke diabetes. Indeed there is no apparent inhibition of effector cell function since active effector cells can transfer diabetes to RIP-TNFci NOD mice (see below).
The possibility that a regulatory cell population controls the function of autoreactive cells present in the spleen of RIP-TNFo~ transgenic mice is unlikely but cannot be conclusively ruled out by our studies. A more detailed study of the kinetics of adoptively transferred mixtures of splenic cells from diabetic mice and splenic cells obtained from RIP-TNFo~ mice to NOD-SCID recipients, using different ratios and perhaps different subsets ofT cells is required before making definitive conclusions. We considered the possibility that the protective effect mediated by TNFol in RIP-TNFo~ transgenic mice might require the continuous presence of TNFcx, for example, to inhibit the action of autoaggressive T cells. To test this possibility, we adoptively transferred diabetic NOD splenic cells or cloned diabetogenic CD8 T cells to irradiated NOD or RIP-TNFcx transgenic mice recipients, and cloned CD8 T cells were also adoptively transferred to non-irradiated recipients. Our data indicated that local expression of TNFci does not protect against effector cells which are already primed in vivo. Taken together, therefore, our results show that local production of TNFci in the islets of Langerhans alters the immune response to this tissue, thereby preventing the development of disease. The protective effect of TNFci, does not appear to require the presence of this cytokine; instead this cytokine confers a long-term protective effect by altering the autoaggresslve potential of cells from these animals. Adoptive transfer experiments suggest a role for TNFci significantly earlier than the delivery of effector function.
The dramatic results that we have seen with TNFIx confirm our recent observations using a second proinflammatory cytokine IL-6 (37). Transgenic NOD mice expressing IL-6, under the control of the RIP, also show reduction in the frequency and rate with which they develop IDDM. The effect of TNFe¢ is, however, much more pronounced than the approximately two-to threefold effect seen in 1KIP-IL-6 transgenic mice (37) . An inflammatory infiltrate is induced in both IL-6 and TNF0¢ transgene mice, but in contrast to TNFcx, the inflammatory infiltrate in IL-6 transgene is found on the NOD genetic background, but not on the diabetes resistant C57BL/6 background. Nonetheless, these results support the concept that a lymphocytic infiltrate mediated by these inflammatory cytokines might play a protective role. We would like to propose that these cytokines recruit cells to the aslets, where they encounter islet auto-antigens expressed at enhanced levels because of the effects of the cytokines. Since islets do not express costimulatory molecules, this encounter between lymphocytes and islet cells expressing MHC-peptide, might receive stimulation only through the antigenic receptor which, under certain circumstances, has been shown to mediate anergy in vitro; in other cases, such encounters have been suggested to cause apoptosis of T cells, perhaps mediated by the stimulation oflFNc~ production (38) . An alternative hypothesis must be considered, however, and that is that the cytokines TNFot and IL-6 have some direct additional protective effects, for example, either on the islets or on the infiltrating cells. Further experiments using mice doubly transgenic mice for TNFci and a diabetogenic TCR are in progress to resolve these issues.
